Cord blood stem cell therapy - Translational Biosciences

Drug Profile

Cord blood stem cell therapy - Translational Biosciences

Alternative Names: human UC-MSC - Translational Biosciences; Human umbilical cord tissue-derived mesenchymal stem cells; huMSC - Translational Biosciences; UC-MSC -Translational Biosciences; Umbilical cord mesenchymal stem cells - Translational Biosciences

Latest Information Update: 11 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Translational Biosciences
  • Class Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 26 Apr 2017 Translational Biosciences withdraws a phase-I/II clinical trial in Osteoarthritis prior to enrolment due to no enrolment in Panama (Intra-articular) (IV) (NCT02237846)
  • 13 Dec 2016 Phase-I/II development is ongoing in Panama
  • 01 Sep 2014 Phase-I/II clinical trials in Osteoarthritis of the knee in Panama (Intra-articular & IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top